Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 27,144 matching trials from the live ClinicalTrials.gov search.
Conditions
Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Interventions
80 mg RPH-104, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Corticosteroid
Drug · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more
Conditions
Pancreatic Cancer
Interventions
Pasireotide (SOM230), placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Laminectomy
Interventions
Esmolol, Saline
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Quantifying Airway Inflammation With Radiologic Tests

NCT00741013
Conditions
Lung Inflammation
Interventions
placebo pill and placebo IV, Lovastatin pill and placebo IV, placebo pill and recombinant human activated protein C IV, Endotoxin
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder

NCT01681849
Conditions
PTSD
Interventions
Placebo, Paroxetine, Positron Emission Tomography (PET) Imaging
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Submental Fat
Interventions
10XB-101 Solution for Injection, 10XB-101 Vehicle Solution for Injection
Drug
Lead sponsor
10xBio, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Encino, California • San Diego, California • Rolling Meadows, Illinois
Conditions
Small Cell Lung Cancer
Interventions
Cisplatin, Etoposide, Placebo, ZD6474
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
19
States / cities
Newark, Delaware • Chicago, Illinois • Galesburg, Illinois + 13 more
Completed Phase 2 Interventional Results available

Ruxolitinib for Premalignant Breast Disease

NCT02928978
Conditions
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Interventions
Ruxolitinib, Placebo (for Ruxolitinib)
Drug
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more
Conditions
Healthy Volunteers
Interventions
SXC-2023, Placebo
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Completed Phase 2 Interventional Results available

Ghrelin Dose Finding In Frail Elderly

NCT01605435
Conditions
The Frailty Syndrome
Interventions
Ghrelin Group 1, Ghrelin Group 2
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
70 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Urinary Bladder, Overactive
Interventions
Placebo, Solifenacin Succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate/vilanterol, fluticasone furoate, vilanterol, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
16,568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
506
States / cities
Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 369 more
Conditions
Panic Disorder
Interventions
placebo, alprazolam XR
Other · Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
3
States / cities
Eugene, Oregon • San Antonio, Texas • Middleton, Wisconsin
Conditions
Osteoarthritis Pain, Chronic Low Back Pain, Pain Due to Interstitial Cystitis
Interventions
placebo, tanezumab
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Overland Park, Kansas
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide, Fluticasone Propionate/Salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 99 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
35
States / cities
Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more
Conditions
Allergic Asthma
Interventions
Albuterol sulfate
Drug
Lead sponsor
Respirics Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Schizophrenia
Interventions
Drug: EVP-6308, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Long Beach, California
Conditions
Chronic Kidney Disease
Interventions
GCS-100, Placebo, Saline
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

NCT03808298
Conditions
Healthy Volunteers
Interventions
Balovaptan therapeutic dose Treatment A, Balovaptan supra-therapeutic dose Treatment B, Active control [moxifloxacin] on Day 2 Treatment C, Active control [Moxifloxacin] on Day 15 Treatment D, Placebo for Balovaptan Treatment C, Placebo for Balovaptan Treatment D, Placebo for Moxifloxacin Treatment A, Placebo for Moxifloxacin Treatment B, Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment D, Moxifloxacin Treatment D
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Major Depressive Disorder
Interventions
ABX-002, Placebo
Drug · Other
Lead sponsor
Autobahn Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 44 more
Conditions
Post Traumatic Stress Disorder
Interventions
JZP150, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
52
States / cities
Phoenix, Arizona • Bryant, Arkansas • Rogers, Arkansas + 45 more
Completed Phase 3 Interventional Results available

Tiotropium Bromide in Cystic Fibrosis

NCT01179347
Conditions
Cystic Fibrosis
Interventions
tiotropium Respimat® inhaler, Placebo Respimat® inhaler
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
15
States / cities
Tuscon, Arizona • San Diego, California • Jacksonville, Florida + 10 more
Conditions
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin 5 mg, Placebo oral tablet
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio